TORONTO, ONTARIO -- (Marketwire) -- 11/19/10 -- Arch Biopartners Inc ("Arch" or the "Company")(CNSX: ACH)(OTC: FOIFF) announced it has agreed to terms on an option to purchase the 1/3 equity stake it does not already own (the "Minority Shares") in its American subsidiary, Colorado Cancer Therapeutics Inc ("CCT"). The Minority Shares are currently owned by University of Colorado ("CU") chemists Dr. Lajos Gera and Dr. Robert Hodges (the "Minority Shareholders"). The Minority Shareholders have granted the sole and exclusive option to the Company to acquire the Minority Shares (the "Option") in return for 500,000 common shares in the capital of
More...
More...